Welcome to the Temple Research Flash, serving the Temple research community with timely news, policy updates, educational opportunities, and the latest funding opportunities from the Temple Research Administration.
The National Institutes of Health (NIH) has issued a final rule revising the definition of principal investigator to include "one or more individuals designated by the grantee in the grant application ... who is or are responsible for the scientific and technical direction of the project," a change from the previous limit of a single PI, the agency announced in the Nov. 10 Federal Register. Full announcement here.
Temple Research Administration is pleased to announce that Dr. Michele Masucci is available to provide assistance to faculty who are interested in developing large cross-cutting research proposals, particularly those being developed in response to funding opportunities from the National Science Foundation. If you are involved in a large scaled or cross cutting opportunity, she can be reached at: 215-204-3597 or at masucci@temple.edu.
Temple Research Administration offices will be closed during the upcoming University holiday break (from close of business Wednesday, December 23, 2009 until 8:30am on Monday, January 4, 2010). Proposals for submission to an external sponsor with a due date between Wednesday, December 23, and Wednesday, January 6, must be submitted to either the Main Campus or HSC Sponsored Projects Administration office no later than Wednesday, December 16. Read the Provost's full announcement here.
The Office of Temple Research Services has announced the next in a series of
eRA@TU webinars.
-----------------------------------------------------------------------------------
Live non-NIH Submission
In the next episode of eRATV we will go over a submission package for a Federal sponsor, not NIH. Different sponsors require different forms and for this demonstration we will review a current submission package (DoD or DoE) live in real time.
When: Tuesday, November 24th, Noon
Where: Wherever you are
URL: http://breeze.temple.edu/eratv
-------------------------------------------------------------------------------------
A panel of subject matter experts will be available to answer your questions during these webinars. You can begin to login 15 minutes prior to the start of the session.
Reminders will be sent the day before the session.
Got a questions? eRA@Temple.edu eRA@TU: Don't be the last to know.
The Office for Human Research Protections (OHRP), Office of Public Health and Science, is announcing the availability of a draft guidance document entitled, ``Guidance on IRB Continuing Review of Research,'' and is seeking comment on the draft guidance. The draft guidance document, when finalized, will represent OHRP's current thinking on this topic and will supersede OHRP's January 15, 2007 guidance document entitled ``Guidance on Continuing Review,'' available at here. The draft document, which is available on the OHRP Web site is intended primarily for institutional review boards (IRBs), investigators, Department of Health and Human Services (HHS) funding agencies, and others that may be responsible for the review, conduct, or oversight of human subject research conducted or supported by HHS. OHRP will consider comments received before issuing the final guidance document.
The office, wishes to let Clinical Investigators know that a finalized Guidance for Industry, Investigator Responsibility—Protecting the Rights, Safety, and Welfare of Study Subjects was issued October 2009, included an Attachment B: Investigator Responsibilities for Significant Risk Device Investigations. The attachment describes specific investigator duties related to investigational medical device trials and their management. This can be accessed at here.
Effective Monday, 9th November 2009, please note our new address:
1938 Liacouras Walk, 2nd floor, Philadelphia, PA 19122
The phone numbers have not changed.
India Patent 236268 was awarded to Temple University on October 14, 2009 for “N-(Aryl)-2-Arylethenesulfonamides.” Drs. E. Premkumar Reddy and M.V. Ramana Reddy in Temple’s Fels Institute for Cancer Research and Molecular Biology jointly created this invention with the late Dr. Stanley Bell at Onconova Therapeutics. Onconova is a Pennsylvania-based biopharmaceutical company that has licensed this technology from Temple University as part of a pipeline of new solutions for cancer, radiation protection and hematological disorders.
Methodological challenges and solutions to studying travel distance to drug markets: A case study of Camden, NJ
Where: Gladfelter Hall 659
When: November 20, 2009, Time: 12:00 p.m.
RSVP: ssdl@temple.edu
Is there variation by market in distance traveled to buy illegal drugs? If so, does it persist after controlling for certain buyer characteristics? Answering these questions requires unique solutions to common research issues including skewed distributions, geocoding, and hotspot identification. Lallen Johnson, Temple Univeristy PhD student in criminal justice, will provide an overview of how to address the above problems using Poisson regression, an alternative geocoding tool, and Nearest Neighbor Hierarchical Clustering, respectively.
New Employee Safety Orientation
When: Monday, November 16, 2009, 9 am to 11 am
Where: Pharmacy/Allied Health Building (HSC) Room B-49
Initial Training for Radioactive Material Users
When: Wednesday, November 18, 2009, 9 am to 4 pm
Where: Pharmacy/Allied Health Building (HSC) Room B-49
Please contact Kisha Grady at kgrady@temple.edu to register for training. Please arrive on time -- anyone arriving later than 15 minutes after beginning of class will be required to reschedule.
